EIK1001

DRUG3 trials

Sponsors

Eikon Therapeutics

Conditions

Advanced MelanomaNSCLCNon Small Cell Lung Cancer (Squamous or Non Squamous)Stage 4 NSCLC

Phase 2

A Phase 2 Study of EIK1001 in Combo With Pembrolizumab and Chemotherapy in Patients With Stage 4 NSCLC

RecruitingNCT06246110

Eikon TherapeuticsNSCLC

Start: 2024-02-06End: 2027-12-31Target: 70Updated: 2025-11-12

Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma.

RecruitingNCT06697301

Eikon TherapeuticsAdvanced Melanoma

Start: 2025-05-22End: 2040-12-31Target: 740Updated: 2025-11-12

A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer.

Not yet recruitingNCT07365319

Eikon TherapeuticsNon Small Cell Lung Cancer (Squamous or Non Squamous), Stage 4 NSCLC

Start: 2026-05-18End: 2040-12-31Target: 750Updated: 2026-01-26

Related Papers

A phase 2 study of EIK1001, a Toll-like receptor 7/8 (TLR7/8) agonist, in combination with pembrolizumab and chemotherapy in patients with stage 4 non-small cell lung cancer.

Journal of Clinical Oncology2024-06-014 citations